The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC

NCT06243679 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Resectable/Potentially Resectable NSCLC

Interventions

DRUG: Immunotherapy

Sponsor

Xiangya Hospital of Central South University